Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung04: rilvegostomig versus pembrolizumab first-line monotherapy for metastatic non-small cell lung cancer with high PD-L1 expression
MOH_2025-02-24_013940Phase 3Recruiting
- Sponsor
- Fortrea
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Rilvegostomig with Pembrolizumab (2 arms). Started Feb 2025; status: recruiting.
02
Drugs
rilvegostomigpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-02-24_013940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-24_013940.